Drug pricing models, no ‘one-size-fits-all’ approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape
The European Journal of Health Economics · 2025-06 · 26 (4) · 683-696
DOI: 10.1007/s10198-024-01731-w ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The European Journal of Health Economics, online erschienen am 04.11.2024. Verfasst von Evert A Manders und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medicine for Society, Platform at Amsterdam University Medical Center, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Drug Costs, Models, Economic. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Access to new medicines is crucial for patients but increasingly sparks discussion due to high prices. Simultaneously, the growing emphasis on specialized products and uncertainty surrounding the long-term effectiveness of new drug classes brought to the market underscore the need for innovative pricing approaches. A systematic literature review of pharmaceutical pricing models, accompanied by a critical appraisal, was conducted to offer insights contributing to novel approaches balancing sustainable pharmaceutical innovation with affordability and accessibility for patients. Six different pricing models are identified: value based pricing, basic cost-based pricing, and four more comprehensive pricing models incorporating numerous elements: the cancer-drug-pricing model, AIM model, (Nuijtens) discounted cash flow, and the real-option rate of return method. Although there are many similarities among the models, each has unique assumptions for implementation. For instance, all models except for the standard incremental cost-effectiveness ratio and basic cost-based pricing consider the number of eligible patients and the remaining patent period. Only the AIM model and the Nuijtens discounted cash flow model use lump sums. Both the latter and the real-option rate of return method explicitly include the cost of capital as a major cost-based component. Recognizing the diverse applications of each model highlights the need for more differential and dynamic pricing tailored to the characteristics and therapeutic areas of each drug. Additionally, the study underscores the importance of cost transparency in achieving this goal. Consequently, these findings can help stakeholders develop sustainable and affordable drug pricing mechanisms that address the complexities of the ever-changing pharmaceutical landscape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medicine for Society, Platform at Amsterdam University Medical Center, Amsterdam, The Netherlands.
- Department of Endocrinology and Metabolism, Amsterdam University Medical Center, Meibergdreef 9, Amsterdam, The Netherlands.
- Centre for Future Affordable & Sustainable Therapy Development (FAST), The Hague, The Netherlands.
- Medicine for Society, Platform at Amsterdam University Medical Center, Amsterdam, The Netherlands. c.e.hollak@amsterdamumc.nl.
- Department of Endocrinology and Metabolism, Amsterdam University Medical Center, Meibergdreef 9, Amsterdam, The Netherlands. c.e.hollak@amsterdamumc.nl.
Zitieren
APA
Manders, E. A., van den Berg, S., de Visser, S. J., & Hollak, C. E. M. (2025). Drug pricing models, no ‘one-size-fits-all’ approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape. The European Journal of Health Economics, 26(4), 683-696. https://doi.org/10.1007/s10198-024-01731-w
Vancouver
Manders EA, van den Berg S, de Visser SJ, Hollak CEM. Drug pricing models, no ‘one-size-fits-all’ approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape. The European Journal of Health Economics. 2025;26(4):683-696. doi:10.1007/s10198-024-01731-w
BibTeX
@article{Manders2025,
author = {Manders, Evert A and van den Berg, Sibren and de Visser, Saco J and Hollak, Carla E M},
title = {Drug pricing models, no ‘one-size-fits-all’ approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape},
journal = {The European Journal of Health Economics},
year = {2025},
volume = {26},
number = {4},
pages = {683--696},
doi = {10.1007/s10198-024-01731-w}
}
EUVIMED